![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
The role of ribavirin in the treatment of Crimean-Congo hemorrhagic fever (CCHF) is scarce. We retrospectively reviewed treatment features of 81 hospitalized patients with laboratory confirmed CCHF between January 2007 and December 2010. The median age of the patients was 45 years and 47 were male. Out of 81 patients, 6 received ribavirin. Demographic characteristics and laboratory findings of the patients who received ribavirin were not different from the patients who did not receive antiviral. There were no statistically significant difference in duration of symptoms before admission (P = 0·47) between the two groups. Of the patients, 29 who did not receive ribavirin and four from the ribavirin treated group had severe disease based on the Swanpoel criteria (P = 0·22). Two patients from each group died. There was no statistically significant difference in case fatality (P = 0·14) and duration of hospitalization (P = 0·11). Treatment of CCHF without ribavirin seems to be safe based on the findings of this study.
Acknowledgements
We thank Ferhan Elmali (Department of Biostatistics, Faculty of Medicine, Erciyes University, Kayseri, Turkey) for help with the statistical analysis. We also want to thank all the staff of the Department of Infectious Diseases for their devoted work during the management of patients with CCHF.
Notes
* Presented at the 5th Eurasia Congress of Infectious Diseases 15-18 May 2013 Tirana/Albania Poster Presentation-83